The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) seeks original papers that address scientific questions, demonstrate new research/developments or contain original scientific results specifically related to the treatment of patients with chronic lymphocytic leukemia (CLL).
The body of the abstract is limited to 700 words or less and must represent original work, although previously published work may be used to fulfill this requirement. Titles, authors, and affiliations are excluded from the total word count of 700 words. Submission of isolated case reports and hypotheses unsupported by data is discouraged. iwCLL reserves the right to reject any abstract for failure to comply with publication guidelines. Encore abstracts will be permitted, however those abstracts published or presented prior to December 1, 2020 will not be accepted. Late breaker abstracts will also be permitted but will only be considered for poster presentations. See Deadlines and Contact below for dates.
Abstract submissions must be made electronically through the submission page found HERE. Tables, figures, graphs, or images are allowed in the abstract submission and must be uploaded separately. The image/table uploads must not be larger than 10MB. The deadline for abstract submission is 30 June 2021. You must withdraw abstracts prior to 23 August 2021. After this time, all accepted abstracts will be included in publication. In the case of abstract acceptance, the Presenting Author (or a Co-Author substitute) must be in attendance (virtually) to present during the meeting. All accepted abstracts will be reprinted for distribution in the online journal, Leukemia and Lymphoma. The XIX iwCLL meeting will include oral presentations for a select group of outstanding submissions and oral poster presentations, and a poster session for those accepted as a poster. Works accepted as oral presenters and oral poster presenters will receive complimentary registration to the main iwCLL meeting for September 17-20. Abstracts accepted as oral presentations to the Young Investigator Meeting will receive complimentary registration to the Young Investigator Meeting (YIM) being held on Friday, September 17th.
Official development assistance (ODA) is defined by the OECD Development Assistance Committee (DAC) as government aid that promotes and specifically targets the economic development and welfare of developing countries. The DAC adopted ODA as the “gold standard” of foreign aid in 1969 and it remains the main source of financing for development aid.
Please see a list of countries here: (link to PDF)
Please note the following dates:
01 August 2021 – Abstract Late-Breakers Open
04 August 2021 – YIM & iwCLL Abstract Notifications
23 August 2021 – Abstract Late-Breakers Closed
23 August 2021 – Abstract Withdrawal Deadline
27 August 2021 – Abstract Titles and Authors Released on Website
01 September 2021 – Late-Breakers Notifications
13 September 2021 – Late-Breakers and Full Abstracts Released on Virtual Platform
Any questions regarding abstract submissions should be sent to iwcll@bioascend.com
Before beginning your abstract submission, you will be asked to login or create an account.
The following information is required in order to submit an abstract.
The Submitting/Presenting Author must provide complete contact information in the Abstract Submission System including:
The Submitting/Presenting Author will receive all future correspondence from iwCLL regarding the status of the abstract, instructions regarding presentation and publishing.
Presenting Authors must also provide co-author information on the first page of the Abstract Submission System including:
Important: Author and Co-author details should be excluded from the abstract upload.
Submissions will be editable prior to the June deadline date when you log back into the Abstract Submission System.
We are excited to announce that the 2021 meeting abstracts have now been published online in the journal supplement of Leukemia and Lymphoma. Please select the link to view the abstracts from this year’s meeting.